Indivior reaches $86 million opioid settlement with 16 US states
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 26 2024
0mins
Should l Buy ?
Source: reuters
Settlement Agreement: Indivior has reached an $86 million settlement with 16 U.S. states regarding its role in the opioid crisis, specifically related to its buprenorphine-based products that were allegedly misused and improperly marketed to doctors.
Ongoing Legal Challenges: The company faces over 400 civil lawsuits for its practices surrounding opioid prescriptions, while the settlement funds will be allocated over five years for addiction treatment and prevention efforts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
